{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:10:55Z","timestamp":1791357055933,"version":"4.3.1"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>This analysis evaluated the tolerability profile of quetiapine using data from all comparative controlled studies in patients with schizophrenia or related disorders in the AstraZeneca clinical trials database, focusing on extrapyramidal symptoms (EPS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adverse event (AE) data from randomised, double\u2010blind, controlled studies in the AstraZeneca clinical trials database were pooled, allowing comparison of quetiapine (mean daily doses 357\u2013496\u2009mg\/day) with placebo, haloperidol (10.4\u2009mg\/day), risperidone (5.5\u2009mg\/day) or chlorpromazine (552\u2009mg\/day). Incidence of EPS\u2010related AEs in relation to quetiapine dose was also analysed using a subset of data from fixed\u2010dose studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from 4956 patients were analysed. Quetiapine was well tolerated, and did not increase EPS\u2010related AEs when compared with placebo (9.6 vs. 10.6%, respectively). The incidence of EPS\u2010related AEs with quetiapine was consistent across the dose range (4.2\u201313.2% vs. 11.1% with placebo). Patients receiving haloperidol, risperidone and chlorpromazine experienced significantly higher levels of EPS\u2010related AEs than those on quetiapine. The most common quetiapine\u2010 associated AEs, with significantly higher incidence than placebo, were sedation, somnolence and orthostatic hypotension.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Quetiapine is generally well tolerated in patients with schizophrenia or related disorders, with placebo\u2010level EPS\u2010related AEs. Quetiapine has a more favourable EPS profile than haloperidol, chlorpromazine or risperidone. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.853","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T11:54:24Z","timestamp":1180698864000},"page":"315-325","source":"Crossref","is-referenced-by-count":21,"title":["An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms"],"prefix":"10.1002","volume":"22","author":[{"given":"Kristina","family":"Timdahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"Stening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-199309000-00005"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125003430"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00190-X"},{"key":"e_1_2_1_5_1","unstructured":"AstraZeneca.2005.Seroquel\u00ae (quetiapine fumarate) tablets\/US prescribing information. Available at:http:\/\/www.astrazeneca\u2010us.com\/pi\/Seroquel.pdf. Accessed 1 Jun. 2006."},{"key":"e_1_2_1_6_1","unstructured":"AstraZeneca Data on file."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199604000-00008"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700038228"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291799001476"},{"key":"e_1_2_1_10_1","unstructured":"Eli Lilly and Company.2005.Zyprexa\u00ae olanzapine tablets\/US prescribing information. Available at:http:\/\/pi.lilly.com\/us\/zyprexa\u2010pi.pdf. Accessed 1 Dec. 2005."},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200015030-00001"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0149-2918(95)80102-2"},{"key":"e_1_2_1_13_1","unstructured":"GoldsteinJM PaulssonB SweitzerD ZhongK.2005.A review of the evidence for somnolence with quetiapine treatment. Abstract published on\u2010line by the American Psychiatric Association (http:\/\/www psych org\/edu\/other_res\/lib_archives\/archives\/meetings\/2005nra.htm)"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(97)88695-1"},{"issue":"1","key":"e_1_2_1_15_1","first-page":"S101","article-title":"Comparison of long\u2010term discontinuation rates during randomised, double\u2010blind treatment with quetiapine or haloperidol in patients with acute psychosis","volume":"21","author":"Jones M","year":"2006","journal-title":"Eur Psychiatry"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00014165"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.6.509"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(99)80722-6"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200507000-00001"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488406775268255"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)89080-3"},{"issue":"1","key":"e_1_2_1_22_1","first-page":"S150","article-title":"Efficacy and tolerability of quetiapine compared with haloperidol in patients with schizophrenia","volume":"3","author":"Murasaki M","year":"2000","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"e_1_2_1_23_1","first-page":"29","article-title":"Extrapyramidal side effects and tolerability of risperidone: a review","volume":"55","author":"Owens DGC","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1997.tb10162.x"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.166.6.712"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867043456043"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199706000-00010"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830180067009"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651500510029192"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JGP.0000196628.12010.35"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216010-00003"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(01)00268-7"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/20.2.297"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00131746-200101000-00005"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/21.3.419"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0712"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.853","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:38:50Z","timestamp":1699958330000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1002\/hup.853"],"URL":"https:\/\/doi.org\/10.1002\/hup.853","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}